These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 36596568)

  • 21. Universal screening and treatment towards the elimination of chronic hepatitis C in China: an economic evaluation.
    Fang K; Wang HL; Lin Y; Zheng L; Li S; Wu J
    Public Health; 2024 Mar; 228():186-193. PubMed ID: 38387115
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hepatitis B screening and vaccination strategies for newly arrived adult Canadian immigrants and refugees: a cost-effectiveness analysis.
    Rossi C; Schwartzman K; Oxlade O; Klein MB; Greenaway C
    PLoS One; 2013; 8(10):e78548. PubMed ID: 24205255
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of the national hepatitis B immunization program in China: a modeling study.
    Liu Z; Li M; Hutton DW; Wagner AL; Yao Y; Zhu W; Cao L; Tang S; Pan J; Wang Y; Zhao Q; Ren H; Wang Y; Wang W
    Infect Dis Poverty; 2022 Oct; 11(1):106. PubMed ID: 36221140
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-Effectiveness of 1-Time Universal Screening for Chronic Hepatitis B Infection in Adults in the United States.
    Toy M; Hutton D; Harris AM; Nelson N; Salomon JA; So S
    Clin Infect Dis; 2022 Jan; 74(2):210-217. PubMed ID: 33956937
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessing the clinical and economic impact of increasing treatment uptake in chronic hepatitis B infection using a Markov model.
    Chinnaratha MA; Kaambwa B; Woodman RJ; Fraser RJ; Wigg AJ
    J Gastroenterol Hepatol; 2017 Jul; 32(7):1370-1377. PubMed ID: 28002881
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessing the cost-effectiveness of treating chronic hepatitis C virus in people who inject drugs in Australia.
    Visconti AJ; Doyle JS; Weir A; Shiell AM; Hellard ME
    J Gastroenterol Hepatol; 2013 Apr; 28(4):707-16. PubMed ID: 23173753
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness analysis of hepatitis B vaccine booster in children born to HBsAg-positive mothers in rural China.
    Wang Y; Shi JF; Wang L; Yan Y; Yao H; Dai M; Chen T; Qu C
    Int J Infect Dis; 2019 Jan; 78():130-139. PubMed ID: 30466898
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness and cost-utility of the treatment of chronic hepatitis B with peginterferon alfa-2a, interferon alfa, and lamivudine in Lithuania.
    Vanagas G; Padaiga Z; Mickevičienė A
    Medicina (Kaunas); 2010; 46(12):835-42. PubMed ID: 21532288
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness analysis of antiviral therapy in patients with advanced hepatitis B virus-related hepatocellular carcinoma treated with sorafenib.
    Zhang P; Yang Y; Wen F; Wheeler J; Fu P; Li Q
    J Gastroenterol Hepatol; 2016 Dec; 31(12):1978-1985. PubMed ID: 27118432
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enhancing the hepatitis B care cascade in Australia: A cost-effectiveness model.
    Xiao Y; Howell J; van Gemert C; Thompson AJ; Seaman CP; McCulloch K; Scott N; Hellard ME
    J Viral Hepat; 2020 May; 27(5):526-536. PubMed ID: 31856377
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness of augmenting universal hepatitis B vaccination with immunoglobulin treatment: a case study in Zhejiang Province, East China.
    Zeng Y; Luo M; Lin J; He H; Deng X; Xie S; Fang Y
    Hum Vaccin Immunother; 2020 Apr; 16(4):955-964. PubMed ID: 31769718
    [No Abstract]   [Full Text] [Related]  

  • 32. Cost-Effectiveness Analysis of Hepatitis B Virus Screening and Management in Patients With Hematologic or Solid Malignancies Anticipating Immunosuppressive Cancer Therapy.
    Hwang JP; Huang D; Vierling JM; Suarez-Almazor ME; Shih YT; Chavez-MacGregor M; Duan Z; Giordano SH; Hershman DL; Fisch MJ; Cantor SB
    JCO Clin Cancer Inform; 2019 Mar; 3():1-12. PubMed ID: 30892921
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessing the cost-effectiveness of hepatitis C screening strategies in France.
    Deuffic-Burban S; Huneau A; Verleene A; Brouard C; Pillonel J; Le Strat Y; Cossais S; Roudot-Thoraval F; Canva V; Mathurin P; Dhumeaux D; Yazdanpanah Y
    J Hepatol; 2018 Oct; 69(4):785-792. PubMed ID: 30227916
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness of non-invasive methods for assessment and monitoring of liver fibrosis and cirrhosis in patients with chronic liver disease: systematic review and economic evaluation.
    Crossan C; Tsochatzis EA; Longworth L; Gurusamy K; Davidson B; Rodríguez-Perálvarez M; Mantzoukis K; O'Brien J; Thalassinos E; Papastergiou V; Burroughs A
    Health Technol Assess; 2015 Jan; 19(9):1-409, v-vi. PubMed ID: 25633908
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness of mass screening for Hepatitis C virus among all inmates in an Irish prison.
    Ward Z; Mafirakureva N; Stone J; Keevans M; Betts-Symonds G; Crowley D; McHugh T; Avramovic G; Lambert JS; Vickerman P
    Int J Drug Policy; 2021 Oct; 96():103394. PubMed ID: 34412938
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Probabilistic cost-effectiveness analysis of the long-term effect of universal hepatitis B vaccination: an experience from Taiwan with high hepatitis B virus infection and Hepatitis B e Antigen positive prevalence.
    Hung HF; Chen TH
    Vaccine; 2009 Nov; 27(48):6770-6. PubMed ID: 19735755
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B infection.
    Jones J; Colquitt J; Shepherd J; Harris P; Cooper K
    Health Technol Assess; 2010 May; 14 Suppl 1():23-9. PubMed ID: 20507800
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Population health impact and cost-effectiveness of monitoring inactive chronic hepatitis B and treating eligible patients in Shanghai, China.
    Toy M; Salomon JA; Jiang H; Gui H; Wang H; Wang J; Richardus JH; Xie Q
    Hepatology; 2014 Jul; 60(1):46-55. PubMed ID: 24990105
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-Effectiveness of Testing and Treatment for Hepatitis B Virus and Hepatitis C Virus Infections: An Analysis by Scenarios, Regions, and Income.
    Tordrup D; Hutin Y; Stenberg K; Lauer JA; Hutton DW; Toy M; Scott N; Chhatwal J; Ball A
    Value Health; 2020 Dec; 23(12):1552-1560. PubMed ID: 33248510
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-Effectiveness of Peg-Interferon, Interferon and Oral Nucleoside Analogues in the Treatment of Chronic Hepatitis B and D Infections in China.
    Goyal A; Murray JM
    Clin Drug Investig; 2016 Aug; 36(8):637-48. PubMed ID: 27166628
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.